Article
Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Cancer research - 1 Dec 1991
Hänninen E L, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J
Abstract excerpt
Different immunotherapy regimens using s.c. recombinant interleukin-2 (rIL-2) were studied in 76 patients with progressive metastatic renal carcinoma, malignant melanoma, colorectal cancer, B-cell lymphoma, or Hodgkin's disease. To assess the immunomodulatory capacity of rIL-2, we measured serum levels of soluble interleukin-2 (sIL-2) receptors, gamma-interferon, tumor necrosis factor-alpha, and various...
Topics
- Carcinoma, Renal Cell
- Colorectal Neoplasms
- Hodgkin Disease
- Humans
- Interferon alpha-2
- Interferon-alpha
- Interferon-gamma
- Interleukin-2
- Kidney Neoplasms
- Killer Cells, Natural
